Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease

Abstract Over 400 variants in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) are CF-causing. CFTR modulators target variants to improve lung function, but marked variability in response exists and current therapies do not address all CF-causing variants highlighting unmet needs....

Full description

Bibliographic Details
Main Authors: Jiafen Gong, Gengming He, Cheng Wang, Claire Bartlett, Naim Panjwani, Scott Mastromatteo, Fan Lin, Katherine Keenan, Julie Avolio, Anat Halevy, Michelle Shaw, Mohsen Esmaeili, Guillaume Côté-Maurais, Damien Adam, Stéphanie Bégin, Candice Bjornson, Mark Chilvers, Joe Reisman, April Price, Michael Parkins, Richard van Wylick, Yves Berthiaume, Lara Bilodeau, Dimas Mateos-Corral, Daniel Hughes, Mary J. Smith, Nancy Morrison, Janna Brusky, Elizabeth Tullis, Anne L. Stephenson, Bradley S. Quon, Pearce Wilcox, Winnie M. Leung, Melinda Solomon, Lei Sun, Emmanuelle Brochiero, Theo J. Moraes, Tanja Gonska, Felix Ratjen, Johanna M. Rommens, Lisa J. Strug
Format: Article
Language:English
Published: Nature Portfolio 2022-04-01
Series:npj Genomic Medicine
Online Access:https://doi.org/10.1038/s41525-022-00299-9

Internet

https://doi.org/10.1038/s41525-022-00299-9

Similar Items